PL2412828T3 - Mutacje K-ras i B-raf i terapia przeciwciałami anty-EGFr - Google Patents

Mutacje K-ras i B-raf i terapia przeciwciałami anty-EGFr

Info

Publication number
PL2412828T3
PL2412828T3 PL11184356T PL11184356T PL2412828T3 PL 2412828 T3 PL2412828 T3 PL 2412828T3 PL 11184356 T PL11184356 T PL 11184356T PL 11184356 T PL11184356 T PL 11184356T PL 2412828 T3 PL2412828 T3 PL 2412828T3
Authority
PL
Poland
Prior art keywords
ras
egfr antibody
antibody therapy
raf mutations
raf
Prior art date
Application number
PL11184356T
Other languages
English (en)
Inventor
Salvatore Siena
Alberto Bardelli
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39666021&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2412828(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PL2412828T3 publication Critical patent/PL2412828T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL11184356T 2007-03-13 2008-03-11 Mutacje K-ras i B-raf i terapia przeciwciałami anty-EGFr PL2412828T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90697607P 2007-03-13 2007-03-13
EP11184356.1A EP2412828B1 (en) 2007-03-13 2008-03-11 K-ras and B-raf mutations and anti-EGFr antibody therapy
EP08742064A EP2118322A2 (en) 2007-03-13 2008-03-11 K-ras and b-raf mutations and anti-egfr antibody therapy

Publications (1)

Publication Number Publication Date
PL2412828T3 true PL2412828T3 (pl) 2013-11-29

Family

ID=39666021

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11184356T PL2412828T3 (pl) 2007-03-13 2008-03-11 Mutacje K-ras i B-raf i terapia przeciwciałami anty-EGFr

Country Status (19)

Country Link
US (2) US20090075267A1 (pl)
EP (2) EP2118322A2 (pl)
JP (3) JP2010521154A (pl)
AR (1) AR065686A1 (pl)
AU (1) AU2008226808B2 (pl)
CA (1) CA2680330A1 (pl)
CL (1) CL2008000716A1 (pl)
CY (1) CY1114159T1 (pl)
DK (1) DK2412828T3 (pl)
ES (1) ES2426814T3 (pl)
HR (1) HRP20130764T1 (pl)
MX (1) MX2009009779A (pl)
PE (1) PE20090690A1 (pl)
PL (1) PL2412828T3 (pl)
PT (1) PT2412828E (pl)
RS (1) RS52932B (pl)
SI (1) SI2412828T1 (pl)
TW (1) TW200904828A (pl)
WO (1) WO2008112274A2 (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007025044A2 (en) * 2005-08-24 2007-03-01 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
ITBO20050646A1 (it) 2005-10-26 2007-04-27 Silicon Biosystem S R L Metodo ed apparato per la caratterizzazione ed il conteggio di particelle
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US12366585B2 (en) 2006-05-18 2025-07-22 Caris Mpi, Inc. Molecular profiling of tumors
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US20080293055A1 (en) 2007-03-13 2008-11-27 Daniel Freeman K-ras mutations and anti-EGFr antibody therapy
PL2412828T3 (pl) * 2007-03-13 2013-11-29 Amgen Inc Mutacje K-ras i B-raf i terapia przeciwciałami anty-EGFr
ITTO20070771A1 (it) 2007-10-29 2009-04-30 Silicon Biosystems Spa Metodo e apparato per la identificazione e manipolazione di particelle
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
US10895575B2 (en) 2008-11-04 2021-01-19 Menarini Silicon Biosystems S.P.A. Method for identification, selection and analysis of tumour cells
IT1391619B1 (it) 2008-11-04 2012-01-11 Silicon Biosystems Spa Metodo per l'individuazione, selezione e analisi di cellule tumorali
EP2350320A4 (en) * 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES
IL313131A (en) * 2009-02-11 2024-07-01 Caris Mpi Inc Molecular characterization of tumors
CN101487051B (zh) * 2009-02-24 2011-07-20 广州益善生物技术有限公司 Braf基因突变的检测探针、液相芯片及其检测方法
US9192943B2 (en) 2009-03-17 2015-11-24 Silicon Biosystems S.P.A. Microfluidic device for isolation of cells
CN102859355B (zh) * 2009-08-24 2015-10-07 基因泰克公司 通过检测kras突变和rtk表达水平来测定细胞对b-raf抑制剂治疗的敏感性
WO2011031840A1 (en) * 2009-09-09 2011-03-17 Quintiles Transnational Corp. Methods and compositions for the treatment of receptor tyrosine kinase mediated diseases or disorders
CN102115782B (zh) * 2009-12-30 2014-06-18 北京雅康博生物科技有限公司 用于定量检测K-ras突变的试剂盒
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
AU2011223655A1 (en) * 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
MX342055B (es) * 2010-04-12 2016-09-12 Response Genetics Inc Iniciadores y sondas de kras.
US9127319B2 (en) 2010-06-15 2015-09-08 Alberto Bardelli MLK4 gene, a new diagnostic and prognostic marker in cancers
AU2011305445B2 (en) 2010-09-24 2017-03-16 The Board Of Trustees Of The Leland Stanford Junior University Direct capture, amplification and sequencing of target DNA using immobilized primers
WO2012049279A1 (en) 2010-10-14 2012-04-19 Universitaet Des Saarlandes MEANS AND METHODS APPLYING SINGLE NUCLEOTIDE PRIMER EXTENSION WITH ION PAIR-, REVERSED-PHASE HPLC (SIRPH) FOR THE DIAGNOSIS OF SNPs
JP5908972B2 (ja) 2011-04-07 2016-04-26 アムジエン・インコーポレーテツド 新規な抗原結合タンパク質
ITTO20110990A1 (it) 2011-10-28 2013-04-29 Silicon Biosystems Spa Metodo ed apparato per l'analisi ottica di particelle a basse temperature
US9023640B2 (en) * 2011-12-13 2015-05-05 Fundamental Solutions Corporation Device for rapid detection of infectious agents
DK2884979T3 (da) 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
CA2886397A1 (en) * 2012-09-26 2014-04-03 Insight Genetics, Inc. Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers
WO2014148557A1 (ja) * 2013-03-19 2014-09-25 凸版印刷株式会社 Ｅｇｆｒ阻害剤感受性予測方法
CN104762371B (zh) 2014-01-07 2021-03-09 三星电子株式会社 用于预测或监控c-Met抑制剂效力的生物标志物
WO2015175705A1 (en) 2014-05-13 2015-11-19 Board Of Regents, The University Of Texas System Gene mutations and copy number alterations of egfr, kras and met
KR20160037666A (ko) 2014-09-29 2016-04-06 삼성전자주식회사 KRAS 또는 BRAF의 변이를 이용한 c-Met 저해제의 효능 예측
CA3001131A1 (en) 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
DK3393537T3 (da) 2015-12-22 2024-08-26 Access Vascular Inc Biomedicinske materialer med høj styrke
AU2018290246A1 (en) 2017-06-21 2020-01-30 Access Vascular, Inc High strength porous materials incorporating water soluble polymers
CN107918013A (zh) * 2017-09-25 2018-04-17 浙江天科高新技术发展有限公司 化学发光酶免测定循环肿瘤细胞中K‑Ras蛋白的方法及试剂盒
CN108085390A (zh) * 2017-12-29 2018-05-29 上海桐树生物科技有限公司 肿瘤驱动基因变异的检测剂、检测试剂盒及其应用
SG11202012653XA (en) 2018-06-19 2021-01-28 Biontech Us Inc Neoantigens and uses thereof
AU2019404045A1 (en) 2018-12-19 2021-06-24 Access Vascular, Inc. High strength porous materials for controlled release
WO2021178785A1 (en) 2020-03-06 2021-09-10 Access Vascular, Inc. Packaging for hydrated articles and related methods
US11992627B2 (en) 2020-06-30 2024-05-28 Access Vascular, Inc. Articles comprising markings and related methods

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
JP2775346B2 (ja) 1992-04-03 1998-07-16 アプライド バイオシステムズ，インコーポレイテッド プローブ構成物および方法
US5470705A (en) 1992-04-03 1995-11-28 Applied Biosystems, Inc. Probe composition containing a binding domain and polymer chain and methods of use
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU775179B2 (en) 1999-03-15 2004-07-22 Applied Biosystems, Llc Probe/mobility modifier complexes for multiplex nucleic acid detection
WO2001092579A2 (en) 2000-05-30 2001-12-06 Pe Corporation (Ny) Methods for detecting target nucleic acids using coupled ligation and amplification
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
WO2003099205A2 (en) 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr
EP2439284B1 (en) * 2004-03-31 2019-05-08 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
AU2005250484B2 (en) 2004-06-04 2011-08-11 Genentech, Inc. EGFR mutations
CA2601936C (en) * 2005-02-24 2014-06-17 Amgen Inc. Epidermal growth factor receptor mutations
US7635570B2 (en) * 2005-04-01 2009-12-22 Salvatore Siena Epidermal growth factor receptor gene copy number
AU2006233675A1 (en) * 2005-04-14 2006-10-19 Merck Patent Gmbh Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues
SI1913157T2 (sl) * 2005-06-28 2017-02-28 Genentech, Inc. EGFR in KRAS mutacije za napoved bolnikovega odziva na zdravljenje z EGFR inhibitorjem
US7908091B2 (en) * 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
KR101053738B1 (ko) * 2006-08-10 2011-08-02 가부시키가이샤 우부카타 세이사쿠쇼 열응동 개폐기
US20080293055A1 (en) * 2007-03-13 2008-11-27 Daniel Freeman K-ras mutations and anti-EGFr antibody therapy
PL2412828T3 (pl) * 2007-03-13 2013-11-29 Amgen Inc Mutacje K-ras i B-raf i terapia przeciwciałami anty-EGFr

Also Published As

Publication number Publication date
HRP20130764T1 (hr) 2013-10-25
PT2412828E (pt) 2013-08-02
AR065686A1 (es) 2009-06-24
JP2013253105A (ja) 2013-12-19
AU2008226808A1 (en) 2008-09-18
SI2412828T1 (sl) 2013-10-30
WO2008112274A2 (en) 2008-09-18
JP5905422B2 (ja) 2016-04-20
EP2412828A1 (en) 2012-02-01
US20110212456A1 (en) 2011-09-01
TW200904828A (en) 2009-02-01
MX2009009779A (es) 2009-09-23
JP2015119726A (ja) 2015-07-02
CY1114159T1 (el) 2016-08-31
HK1167005A1 (en) 2012-11-16
DK2412828T3 (da) 2013-09-02
CA2680330A1 (en) 2008-09-18
RS52932B (sr) 2014-02-28
US20090075267A1 (en) 2009-03-19
EP2118322A2 (en) 2009-11-18
EP2412828B1 (en) 2013-06-05
ES2426814T3 (es) 2013-10-25
JP2010521154A (ja) 2010-06-24
CL2008000716A1 (es) 2008-09-22
AU2008226808B2 (en) 2013-04-18
WO2008112274A3 (en) 2008-12-18
PE20090690A1 (es) 2009-06-22

Similar Documents

Publication Publication Date Title
SI2412828T1 (sl) Mutacije k-ras in b-raf ter terapija s protitelesom anti-egfr
LT2465950T (lt) K-ras mutacijos ir anti-egfr antikūnų terapija
EP2038041A4 (en) THERAPEUTIC COMPOUNDS AND THEIR USE AGAINST CANCER
ZA200905886B (en) Methods and kits for administering probiotics
EP2180873A4 (en) THERAPEUTIC DENTAL COMPOSITION AND RELATED METHODS
GB0803018D0 (en) Therapeutic compounds and their use
GB0804685D0 (en) Therapeutic compounds and their use
GB0724251D0 (en) Therapeutic compounds and their use
GB0807609D0 (en) Therapeutic compounds and their use
EP2004637A4 (en) SUBSTITUTED RING-CONDENSED AZINES AND THEIR USE IN CANCER THERAPY
PT2162118T (pt) Microesferas porosas e sua utilização em terapia
GB0722680D0 (en) Therapeutic compounds and their use
GB0807018D0 (en) Antibodies and treatment
GB2460181B (en) Depsipeptides and their therapeutic use
GB2460178B (en) Depsipeptides and their therapeutic use
IL206420A0 (en) Azetidine derivatives, their preparation and their application in therapy
EP2097085A4 (en) THERAPEUTIC MATERIALS AND METHOD
GB0812913D0 (en) Therapeutic compounds and their use
GB0607949D0 (en) Mono and combination therapy
GB0607946D0 (en) Mono and combination therapy
GB2460180B (en) Depsipeptides and their therapeutic use
HK1139182A (en) K-ras and b-raf mutations and anti-egfr antibody therapy
GB0818663D0 (en) Gene regulation and its use in therapy
GB0802128D0 (en) Therapeutic compounds and their use
EP2234667A4 (en) DETERMINATION AND METHODS OF ADMINISTERING A TREATMENT